@article{b1578090eaf3401084cb0144e9dafc2f,
title = "Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary",
keywords = "brentuximab vedotin, classical Hodgkin lymphoma, dacarbazine, doxorubicin, early-stage, nivolumab, Plain language summary",
author = "Abramson, \{Jeremy S.\} and Straus, \{David J.\} and Bartlett, \{Nancy L.\} and Burke, \{John M.\} and Lynch, \{Ryan C.\} and \{Domingo Domenech\}, Eva and Brian Hess and Schuster, \{Steven R.\} and Yuliya Linhares and Mitul Gandhi and Shah, \{Harsh R.\} and Wojciech Jurczak and Alessandro Re and Uwe Hahn and Prince, \{H. Miles\} and Wenchuan Guo and Griffith Davis and Linda Ho and Michelle Fanale and Yasenchak, \{Christopher A.\} and Lee, \{Hun Ju\}",
note = "Publisher Copyright: {\textcopyright} 2026 The Author(s). Published by Informa UK Limited, trading as Taylor \& Francis Group.",
year = "2026",
doi = "10.1080/14796694.2026.2693614",
language = "English",
volume = "22",
pages = "2027--2040",
journal = "Future Oncology",
issn = "1479-6694",
number = "17",
}